Acquisition by Kim Anthony H. of 160000 shares of Marker Therapeutics at 0.46 subject to Rule 16b-3
| MRKR Stock | USD 3.19 0.07 2.15% |
Slightly above 62% of Marker Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Marker Therapeutics stock suggests that many investors are alarmed at this time. Marker Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Marker Therapeutics. Many technical investors use Marker Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Marker |
Filed transaction by Marker Therapeutics Officer Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Marker Therapeutics Fundamental Analysis
We analyze Marker Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marker Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marker Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Marker Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Marker Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Marker Therapeutics stock to make a market-neutral strategy. Peer analysis of Marker Therapeutics could also be used in its relative valuation, which is a method of valuing Marker Therapeutics by comparing valuation metrics with similar companies.
Peers
Marker Therapeutics Related Equities
| XCUR | Exicure | 15.53 | ||||
| BNOX | Bionomics | 7.14 | ||||
| AGEN | Agenus | 3.25 | ||||
| ACRV | Acrivon Therapeutics, | 2.31 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
| TPST | Tempest Therapeutics | 2.13 | ||||
| KROS | Keros Therapeutics | 2.02 | ||||
| PMVP | Pmv Pharmaceuticals | 0.63 | ||||
| EWTX | Edgewise Therapeutics | 0.37 | ||||
| LUMO | Lumos Pharma | 0.46 | ||||
| ALEC | Alector | 0.78 | ||||
| IKNA | Ikena Oncology | 1.17 | ||||
| AADI | Aadi Bioscience | 1.30 | ||||
| AVTE | Aerovate Therapeutics | 1.49 | ||||
| RNXT | RenovoRx | 7.35 | ||||
| PTIX | Protagenic Therapeutics | 17.81 |
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.